Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage oncology company with Nasdaq-traded American depositary shares. Form 6-K reports furnish investor presentations, fact sheets, clinical updates for paxalisib, material-event disclosures, operating and financial results, and updates related to the company's oncology pipeline.
The filing record also covers capital structure and financing activity, including ADS sales agreements, registration-statement references, private placements, ordinary shares, pre-funded warrants, and placement-agent warrants. Governance disclosures include annual general meeting results, director and committee changes, and shareholder voting matters. Material-agreement filings describe licensing arrangements such as the SETDB1-targeted epigenetic platform, while risk and forward-looking disclosures address development-stage biotechnology, regulatory plans, clinical programs, and capital-market compliance.
Kazia Therapeutics director Steven R. S. Coffey filed an initial ownership report showing his equity interests in the company. He holds options over 1,000 American Depositary Shares (ADSs) at an exercise price of $0.3348 expiring on April 30, 2027, granted on April 30, 2024 with quarterly vesting over three years, and options over 75,000 ADSs at $8.00 expiring on July 3, 2027, which vested fully on July 3, 2025. He also directly owns 16,000 ordinary shares. Additional ADS holdings of 845 and 1,122 are held by Coffey Family Investments Pty Limited and Fortune 501 Pty Limited, respectively, and Coffey disclaims beneficial ownership of those securities except for any pecuniary interest. Each ADS may be exchanged at any time for 500 ordinary shares, and the ADSs themselves have no expiration date.
Kazia Therapeutics filed an initial ownership report for Chief Executive Officer John E. Friend II, showing he holds several option awards rather than recent market trades. These options give him the right to buy both American Depositary Shares (ADSs) and ordinary shares at preset prices before their expiration dates.
He holds ADS options over 30,000 ADSs at an exercise price of $0.3770 per ADS expiring on July 22, 2027, and over 500,000 ADSs at $6.5800 per ADS expiring on July 3, 2027. He also holds ordinary share options over 3,000,000 shares at $0.1323 per share expiring on May 3, 2027, and 1,000,000 ordinary shares at $0.1061 per share expiring on March 3, 2027.
Footnotes explain that these options vest in quarterly or annual installments starting between 2023 and 2025, subject to his continued service, and that exercise prices are reported in U.S. dollars based on a stated AUD/USD exchange rate. No purchases or sales occurred; this filing mainly outlines his existing equity-based compensation.
Kazia Therapeutics Program Director Jeremy Simpson filed an initial Form 3 reporting existing option holdings in the company. He holds options over 280,000 ordinary shares with a $0.1061 exercise price expiring on March 3, 2027, and options over 100,000 ordinary shares with a $0.6651 exercise price expiring on February 1, 2027. Footnotes explain these options were granted in 2022 and 2023 and vest in scheduled installments, reflecting compensation awards rather than new market transactions.
Kazia Therapeutics VP, Finance and Controller Jeffrey Bonacorda has reported initial holdings of stock options over American Depositary Shares. The filing shows options over 5,000 ADSs at an exercise price of 0.23 expiring on 2028-06-24, and options over 100,000 ADSs at 6.58 expiring on 2027-07-03. These awards vest in annual installments starting on June 24, 2024 and July 3, 2025, contingent on continued service.
Kazia Therapeutics Ltd director Robert F. Apple filed his initial ownership report, showing two American Depositary Share (ADS) option awards. One ADS option covers 2,000 underlying ADSs at an exercise price of $0.3348 per ADS, expiring on April 30, 2027, and vests in equal quarterly installments over three years beginning on April 30, 2024. A second ADS option covers 75,000 underlying ADSs at an exercise price of $6.58 per ADS, expiring on July 3, 2027, and vests in three equal annual installments beginning on July 3, 2025. Each option converts into ADSs upon exercise, and each ADS may be represented by 500 ordinary shares of Kazia Therapeutics.
Kazia Therapeutics Limited filed a Form F-3 shelf registration to offer up to $200,000,000 of securities, consisting of American Depositary Shares (each representing 500 ordinary shares) and warrants, with specific offerings to be detailed in prospectus supplements.
A prospectus supplement dated March 17, 2026 sets out an at-the-market sales agreement with Leerink Partners LLC for up to $100,000,000 of ADSs. The supplement states sales will be made on an at-the-market basis and that Leerink Partners will receive a 3.0% commission on gross proceeds.
The ADSs trade on Nasdaq under the symbol KZIA; the supplement cites a last reported sale price of $8.01 per ADS on March 12, 2026. Offerings under the shelf and the sales agreement are subject to prospectus supplements and the registration statement becoming effective.
Kazia Therapeutics Ltd ownership filing: Jorey Chernett reports beneficial ownership of 1,412,662 ADS, representing 12.46% of the American Depositary Shares as of February 19, 2026. The percent is calculated using 11,335,991 ADS outstanding as of December 11, 2025, per the issuer's prospectus.
The filing is an amendment to a previously reported Schedule 13G and lists the Reporting Person's principal business address in Bloomfield Hills, Michigan, and U.S. citizenship.
Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G reporting a 5.1% beneficial stake in Kazia Therapeutics Limited. They report beneficial ownership of 580,754 American Depositary Shares, each ADS representing five-hundred ordinary shares of Kazia.
The ADSs may be acquired within 60 days by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts advised by Ikarian Capital. The holders state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Kazia.
Kazia Therapeutics Ltd received an amended Schedule 13G filing from Dauntless Investment Group, LLC covering its holdings of Kazia American Depositary Shares. As of the event date of 12/31/2025, Dauntless reports beneficial ownership of 1 American Depositary Share, representing 0.0% of the class.
Dauntless reports no sole or shared voting power over any shares and sole dispositive power over 1 share. The filer identifies itself as a single family office/passive investor and certifies that the securities are not held for the purpose of changing or influencing control of Kazia.
Kazia Therapeutics Limited files a prospectus supplement covering 266,666 American Depositary Shares, representing 133,333,000 ordinary shares, and updates investors using a newly furnished Form 6-K.
The attached report highlights encouraging early results from an ongoing Phase 1b study of paxalisib in late-stage metastatic triple-negative breast cancer. Three patients treated with paxalisib-based regimens have shown meaningful clinical responses, including two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient.
Paxalisib in combination with pembrolizumab and chemotherapy has been generally well tolerated, with most adverse events deemed unlikely or unrelated to paxalisib and reported paxalisib-related events mainly mild to moderate. Kazia plans to activate additional clinical sites in 2026, aims to enroll twelve triple-negative breast cancer patients by the end of 2026, and anticipates topline data in early 2027.